Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anju Ghangurde

Executive Editor, APAC

Anju is Deputy Asia Editor at Scrip & Pink Sheet. She has over two decades of experience in journalism including stints at India's leading financial dailies. Based in Mumbai, India, she covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Latest From Anju Ghangurde

Dissecting Piramal’s Damages Award In Sensipar Case

A legal expert details how Piramal Healthcare could turn the tables and secure damages in the litigation pertaining to its generic version of Amgen's Sensipar, a case which saw multiple at-risk launches.

Legal Issues Generic Drugs

Pre-work Rigour, 'Clean' Documentation Key As FDA Unlocks Remote Inspection Tools

A senior Parexel executive and ex-FDA pharmaceutical quality assessor emphasizes at a conclave why “first impressions matter now more than ever” as the agency  deploys complex alternate inspections tools which the pandemic provided, and that companies need to ensure that they get things right the first time.

Manufacturing Compliance

Boehringer Ingelheim’s Formula For Scaling Transformation, Digitization

Boehringer Ingelheim’s corporate senior vice president, head of global regions, Timmo Rousku Andersen, outlines at a recent summit the company’s reshaped approach to digital innovation and the need to entrench an execution bias to scale transformation initiatives.

Commercial Digital Health

'Incorrect' To Assume Interchangeables Are Safer, More Effective Than Biosimilars, Says FDA

US FDA India country director Dr Sarah McMullen provides a fact check at a recent conclave to dispel the notion that interchangeable biosimilars are safer and more effective than other approved biosimilars.

Biosimilars Drug Safety

Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India

India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.

Policy India

Pharma Readies For Price Caps On Glargine, Teneligliptin, Lenalidomide In India

India’s national list of essential medicines 2022 features 34 additions, including insulin glargine, teneligliptin, lenalidomide, bedaquiline and montelukast, with price control expected to follow on these drugs.

Policy India
See All
UsernamePublicRestriction

Register